NASDAQ:RGNX - Regenxbio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $44.72 -1.42 (-3.08 %) (As of 05/19/2019 04:25 AM ET)Previous Close$44.72Today's Range$44.64 - $45.9152-Week Range$38.56 - $85.10Volume373,795 shsAverage Volume508,551 shsMarket Capitalization$1.64 billionP/E Ratio18.79Dividend YieldN/ABeta0.37 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Receive RGNX News and Ratings via Email Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX Previous Symbol CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone240-552-8181Debt Debt-to-Equity Ratio0.01 Current Ratio14.21 Quick Ratio14.21Price-To-Earnings Trailing P/E Ratio18.79 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$218.51 million Price / Sales7.50 Cash Flow$2.4886 per share Price / Cash Flow17.97 Book Value$13.29 per share Price / Book3.36Profitability EPS (Most Recent Fiscal Year)$2.38 Net Income$99.94 million Net Margins-41.99% Return on Equity-9.90% Return on Assets-9.35%Miscellaneous Employees192 Outstanding Shares36,640,000Market Cap$1.64 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Regenxbio (NASDAQ:RGNX) Frequently Asked Questions What is Regenxbio's stock symbol? Regenxbio trades on the NASDAQ under the ticker symbol "RGNX." How were Regenxbio's earnings last quarter? Regenxbio Inc (NASDAQ:RGNX) issued its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.04. The biotechnology company earned $0.88 million during the quarter. Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. View Regenxbio's Earnings History. When is Regenxbio's next earnings date? Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Regenxbio. What price target have analysts set for RGNX? 7 equities research analysts have issued 12 month target prices for Regenxbio's shares. Their predictions range from $42.00 to $127.50. On average, they anticipate Regenxbio's share price to reach $81.6786 in the next year. This suggests a possible upside of 82.6% from the stock's current price. View Analyst Price Targets for Regenxbio. What is the consensus analysts' recommendation for Regenxbio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 sell rating, 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio. Has Regenxbio been receiving favorable news coverage? Media coverage about RGNX stock has been trending negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regenxbio earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Regenxbio's key competitors? Some companies that are related to Regenxbio include argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX) and Alector (ALEC). What other stocks do shareholders of Regenxbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include Micron Technology (MU), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Bank of America (BAC), Gilead Sciences (GILD), Immunomedics (IMMU), Bausch Health Companies (BHC), Square (SQ) and Incyte (INCY). Who are Regenxbio's key executives? Regenxbio's management team includes the folowing people: Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)Dr. Olivier Danos, Chief Scientific Officer (Age 61)Dr. Stephen Yoo, Consultant (Age 41) Who are Regenxbio's major shareholders? Regenxbio's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.32%), JPMorgan Chase & Co. (3.29%), Perceptive Advisors LLC (3.13%), Perceptive Advisors LLC (3.13%), Renaissance Technologies LLC (2.37%) and FMR LLC (2.36%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio. Which major investors are selling Regenxbio stock? RGNX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Wellington Management Group LLP, FMR LLC, AQR Capital Management LLC, Voya Investment Management LLC, Renaissance Technologies LLC, Pinebridge Investments L.P. and Goldman Sachs Group Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio. Which major investors are buying Regenxbio stock? RGNX stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, SG Americas Securities LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Acadian Asset Management LLC and Pier Capital LLC. View Insider Buying and Selling for Regenxbio. How do I buy shares of Regenxbio? Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Regenxbio's stock price today? One share of RGNX stock can currently be purchased for approximately $44.72. How big of a company is Regenxbio? Regenxbio has a market capitalization of $1.64 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe. What is Regenxbio's official website? The official website for Regenxbio is http://www.regenxbio.com. How can I contact Regenxbio? Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected] MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 285 (Vote Outperform)Underperform Votes: 231 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What causes a recession? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.